Simulations Plus, Inc. develops drug discovery and development software for mechanistic modeling and simulation, and machine-learning-based prediction of properties of molecules from their structure worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments that measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus, which simulates laboratory experiments. It also provides PKPlus, a standalone program that provides the functionality needed by pharmaceutical industry scientists to perform the analyses and generate the outputs needed to satisfy regulatory agency requirements for NCA and compartmental PK modelling; ADMET Predictor, a chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, a molecule drawing program or sketcher. In addition, it offers MedChem Studio, a software tool for data mining and designing new molecules; KIWI, a cloud-based Web application to organizes, processes, maintains, and communicates the volume of data and results generated by pharmacologists and scientists over the duration of a drug development program; DILIsym, a quantitative systems pharmacology software; NAFLDsym, a simulation program for analyzing nonalcoholic fatty liver disease; and RENAsym for investigating and predicting drug-induced or acute kidney injury. Further, the company provides population modeling and simulation contract research services for the pharmaceutical and biotechnology industries; and clinical-pharmacology-based consulting services in support of regulatory submissions. It sells its pharmaceutical/chemistry software to pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies. The company was founded in 1996 and is headquartered in Lancaster, California.
Industry, Sector and Symbol
Industry Computer integrated systems design
Sub-IndustryN/A
SectorComputer and Technology
Phone661-723-7723
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$29.67 million
Profitability
Miscellaneous
Employees95
OptionableOptionable
Simulations Plus (NASDAQ:SLP) Frequently Asked Questions
What is Simulations Plus' stock symbol?
Simulations Plus trades on the NASDAQ under the ticker symbol "SLP."
How often does Simulations Plus pay dividends? What is the dividend yield for Simulations Plus?
Simulations Plus declared a quarterly dividend on Thursday, January 10th. Stockholders of record on Friday, January 25th will be given a dividend of $0.06 per share on Friday, February 1st. This represents a $0.24 annualized dividend and a dividend yield of 1.27%. The ex-dividend date of this dividend is Thursday, January 24th. View Simulations Plus' Dividend History.
How were Simulations Plus' earnings last quarter?
Simulations Plus, Inc. (NASDAQ:SLP) released its earnings results on Wednesday, January, 9th. The technology company reported $0.09 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.11 by $0.02. The technology company earned $7.54 million during the quarter, compared to analyst estimates of $7.45 million. Simulations Plus had a return on equity of 23.26% and a net margin of 29.05%. View Simulations Plus' Earnings History.
When is Simulations Plus' next earnings date?
What guidance has Simulations Plus issued on next quarter's earnings?
Simulations Plus updated its FY 2019 earnings guidance on Wednesday, January, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $32.633-34.117 million, compared to the consensus revenue estimate of $32.5 million.
What is the consensus analysts' recommendation for Simulations Plus?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Simulations Plus in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Simulations Plus.
Has Simulations Plus been receiving favorable news coverage?
News stories about SLP stock have trended negative this week, according to InfoTrie. The research firm identifies positive and negative news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Simulations Plus earned a news sentiment score of -2.1 on InfoTrie's scale. They also assigned press coverage about the technology company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an effect on the stock's share price in the next several days.
Who are some of Simulations Plus' key competitors?
Some companies that are related to Simulations Plus include Nextgen Healthcare (NXGN), Sykes Enterprises (SYKE), Unisys (UIS), Ribbon Communications (RBBN), Onespan (OSPN), Agilysys (AGYS), KEYW (KEYW), Pareteum (TEUM), Digimarc (DMRC), Aerohive Networks (HIVE), Borqs Technologies (BRQS), Travelzoo (TZOO), Asure Software (ASUR), CSP (CSPI) and AgriVest Americas (NXCN).
Who are Simulations Plus' key executives?
Simulations Plus' management team includes the folowing people:
- Mr. Walter S. Woltosz, Co-Founder & Chairman (Age 74)
- Mr. Shawn M. O'Connor, Chief Exec. Officer (Age 59)
- Mr. John R. Kneisel, Chief Financial Officer (Age 61)
- Dr. Thaddeus Henry Grasela Jr., Pharm.D., PharmD, Ph.D., Pres Buffalo Division, Director of Simulations Plus & Director (Age 65)
- Mr. John Anthony DiBella, Pres of the Lancaster Division (Age 39)
Who are Simulations Plus' major shareholders?
Simulations Plus' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Strs Ohio (0.17%) and Bank of Montreal Can (0.07%). Company insiders that own Simulations Plus stock include Argenio David Z D, John Robert Kneisel, Thaddeus Henry Grasela Jr, Virginia E Woltosz and Walter S Woltosz. View Institutional Ownership Trends for Simulations Plus.
Which institutional investors are selling Simulations Plus stock?
SLP stock was sold by a variety of institutional investors in the last quarter, including Strs Ohio and Bank of Montreal Can. Company insiders that have sold Simulations Plus company stock in the last year include John Robert Kneisel and Walter S Woltosz. View Insider Buying and Selling for Simulations Plus.
How do I buy shares of Simulations Plus?
Shares of SLP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Simulations Plus' stock price today?
One share of SLP stock can currently be purchased for approximately $18.87.
How big of a company is Simulations Plus?
Simulations Plus has a market capitalization of $329.47 million and generates $29.67 million in revenue each year. The technology company earns $8.93 million in net income (profit) each year or $0.50 on an earnings per share basis. Simulations Plus employs 95 workers across the globe.
What is Simulations Plus' official website?
How can I contact Simulations Plus?
Simulations Plus' mailing address is 42505 10TH STREET WEST, LANCASTER CA, 93534. The technology company can be reached via phone at 661-723-7723 or via email at [email protected]
MarketBeat Community Rating for Simulations Plus (NASDAQ SLP)
MarketBeat's community ratings are surveys of what our community members think about Simulations Plus and other stocks. Vote "Outperform" if you believe SLP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SLP will underperform the S&P 500 over the long term. You may vote once every thirty days.
